People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

Nandita Vijayasimha, Bengaluru Thursday, February 6, 2025, 08:00 Hrs [IST] ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...